Mainz Biomed shares rise 17.32% premarket after pancreatic cancer biomarker panel achieves 100% sensitivity and 95% specificity, with public funding secured.

Mainz Biomed surged 17.32% in premarket trading following the release of its 2025 business highlights, which included a 100% sensitivity and 95% specificity result for its pancreatic cancer biomarker panel in a feasibility study. The company also announced the initiation of eAArly DETECT 2, a U.S. clinical trial for its next-generation colorectal cancer test, and secured regulatory approvals for ColoAlert in the UK and Switzerland. Strategic partnerships in Europe, including collaborations with Swiss and German labs, further reinforced growth prospects. These developments, coupled with public funding for its pancreatic cancer project, positioned the stock for a sharp rise, reflecting investor optimism over clinical progress and market expansion.